The potential outcomes and benefits of the use of biotechnology are numerous, infinitely beneficial, and therefore its recognition as a key enabler of the EUs goals and aspirations is a natural progression. We therefore welcome the European Commissions renewed intention to capitalise on this technology to meet its strategic goals of transitioning to a greener planet and economy, providing safer, affordable…
LAL
Lallemand
Company · Canada
2
positions filed
in the 326 files tracked
2
legislative files
of 326 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track Lallemand in PolicySpeak: request access →
Work at Lallemand? so we know who speaks for it.
Their record over time
Lallemand filed 2 positions between 11 Jun 2025 and 10 Jun 2026, across 2 of the 326 legislative files tracked here, attaching a full position paper 1 time.
2025 · 1 filed2026 · 1 filed
What they argued
Lallemand welcomes and supports European Commissions initiative which should strengthen Europes leadership positioning and competitiveness in biotechnology and biomanufacturing. Biotech Act II must therefore be bold, ambitious and future proof; demonstrate its support of EU productivity (capacity) and innovation.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 2 files in common
- Cefic · 2 files in common
- Danish Industry · 2 files in common
- German Association of Biotechnology Industries (DIB) within the German Chemical Industry Association - VCI · 2 files in common
- BASF SE · 2 files in common
Showing 5 of 80.
Is this your organization?
Everything on this page comes from Lallemand’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.